A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms Celest
  • Sponsors AbbVie
  • Most Recent Events

    • 01 Nov 2017 Results assessing exposure-response relationships between upadacitinib plasma exposures and the clinical and endoscopic efficacy endpoints, presented at the 25th United European Gastroenterology Week.
    • 01 Nov 2017 Results assessing patient-reported outcomes, presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top